← Human Trials & Peer-Reviewed Studies
A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency.
Plain-language guide to PMID 39607675 (2025): multicenter randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 391 participants.
Key Facts
- PMID
- 39607675
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Liang Y et al. (29 authors)
- DOI
- 10.1210/clinem/dgae816
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Who Took Part
The study group was 391 participants.
By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.
A multicenter, randomized, controlled phase 3 clinical trial was conducted at 23 centers in China with a duration of 52 weeks' treatment.
There were 391 pediatric participants diagnosed with GHD.
How the Study Was Run
In design terms this was a randomized and multicenter study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
More than one site took part, so the participants came from several places.
The primary end point was the growth velocity (GV) at 52 weeks, and the secondary end points mainly involved changes from baseline in height SD scores for chronological age and bone age (ΔHt SDS CA and ΔHt SDS BA).
What Was Measured
Topics PubMed links to this paper include Body Height, China, Dwarfism, Pituitary, Growth Disorders, Human Growth Hormone, Polyethylene Glycols and Recombinant Proteins.
Author keywords: Y-shape pegylated rhGH, growth hormone deficiency, long-acting growth hormone and pediatric.
What This Means in Plain Language
The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 391 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.